Nasdaq TSLA Tesla

General Motors Co on Monday cut the starting price for the Cadillac Lyriq in China by almost 14%, joining Volkswagen in a new round of electric vehicle price reductions in a market where global automakers are under pressure.

New electric vehicles from Tesla and rivals are being engineered for efficiency in a way that cuts copper content, changes that could limit demand growth for the metal as the next-generation of EVs hits the road, industry analysts say.

Thailand's Siam Motors partnered with Nissan Motors in 1962 with a factory that rolled out four cars a day, leading to a profitable, decades-long relationship with Japanese companies that transformed it from a car dealer to an automotive pioneer.

Below is Validea's guru fundamental report for TESLA INC (TSLA). Of the 22 guru strategies we follow, TSLA rates highest using our Small-Cap Growth Investor model based on the published strategy of Motley Fool. This strategy looks for small cap growth stocks with solid fundament

ChargePoint (NYSE: CHPT) is jumping into the NACS game as electric vehicles (EVs) adopt the charging standard, but is that a sign of weakness or strength? Travis Hoium covers that and some other red flags for Chargepoint.

The market is off to a red-hot start this year, up more than 15% as we enter the second half of 2023, and investors from retail to institutional have done well, including some of the richest people in the world. After the market fell about 20% in 2022, America's billionaires, man

Electric vehicles (EVs) are changing the auto industry. Costs have come down, consumers are interested and buying, and every automaker from startup to legacy giant is putting serious money behind their EV ambitions. But just as with any mass-market product adoption, there remain

Fool.com contributor Parkev Tatevosian discusses why a pact among rivals to stop the price war could be great news for Tesla (NASDAQ: TSLA) and Nio (NYSE: NIO) stock investors.

The fear of the U.S. Federal Reserve resuming interest rate hikes soon has reinforced fears of an impending recession. Investors with a long-term horizon could benefit by looking at attractive value stocks – stocks of companies trading at lower prices than what the fundamentals suggest. Using TipRanks’ Stock Comparison Tool, we placed PepsiCo ( NASDAQ:PEP ), AbbVie ( NYSE:ABBV ), and General Motors ( NYSE:GM ) against each other to find the value stock that has the highest upside potential as per Wall Street analysts. PepsiCo (NASDAQ:PEP) PepsiCo’s stock movement has been unimpressive this year despite better-than-anticipated first-quarter earnings. The company’s pricing power and robust presence in the snack food and beverage space helped deliver upbeat Q1 results and increase the full-year outlook.  Ahead of PepsiCo’s Q2 results (scheduled on July 13), Goldman Sachs analyst Bonnie Herzog reaffirmed a Buy rating on PEP with a price target of $208, saying that he sees a “favorable risk-reward.” The analyst expects a “healthy” revenue and earnings beat, given continued momentum in the company’s businesses, particularly for Frito-Lay North America (FLNA) as noted in recent NielsenIQ data. Furthermore, Herzog highlighted that the trends in the PepsiCo Beverages North America (PBNA) segment appear healthy, with consumer elasticities being resilient despite a tough macro backdrop. Consequently, the analyst raised his Q2 organic sales growth expectation to 11.1% from 9.8%, mainly to reflect FLNA strength, and also increased his EPS estimate. Overall, Herzog believes that PepsiCo is one of the “best positioned companies” in the global food and beverage space to generate solid growth over the next ten years due to its impressive exposure to the snack food space and developing and emerging markets. Is PEP Stock a Buy Now? With six Buys and five Holds, PEP stock scores a Moderate Buy consensus rating. At $195.90, the average price target implies 7% upside. Shares have risen 1.3% so far this year. PEP, a dividend king, offers a dividend yield of 2.8%. AbbVie (NYSE:ABBV) Shares of AbbVie have been under pressure due to investors’ concerns about the declining sales of the pharma company’s immunology drug Humira due to competition from Biosimilars. Humira sales declined 25.2% to $3.5 billion in Q1 2023, dragging down overall sales by 9.7% to $12.2 billion.  On Thursday, the company lowered its full-year adjusted EPS outlook, citing $280 million in milestone and in-process research and development expenses during the second quarter. The company now expects full-year adjusted EPS between $10.57 and $10.97 per share. Moreover, the company’s Q2 EPS guidance missed analysts’ expectations.  While near-term pressure seems inevitable, AbbVie is optimistic about the road ahead and expects its newer immunology drugs Skyrizi and Rinvoq to deliver sales of over $17.5 billion in 2025. Moreover, as of late May, the company’s pipeline had more than 50 programs in the mid and late-stage development.  It is worth noting that AbbVie has increased its dividend for 51 consecutive years [including the years it was part of Abbott Laboratories ( NYSE:ABT )]. The company offers a dividend yield of 4.4%. Is ABBV Stock a Buy or Sell? Wall Street is cautiously optimistic on AbbVie stock, with a Moderate Buy consensus rating based on six Buys and five Holds. The average price target of $169.10 implies nearly 25% upside. The stock has declined 16% year-to-date. General Motors (NYSE:GM) Legacy automaker General Motors is rapidly moving ahead with its goal to become an all- electric vehicle (EV) company. According to a report by Motor Intelligence, cited by CNBC, Tesla ( NASDAQ:TSLA ) continued to be the U.S. EV market leader in the first half of 2023 and sold 336,892 vehicles (up 30% year-over-year). A distant second was Hyundai (including the Kia brand) ( HYMTF ), which sold 38,457 EVs in the first half. Meanwhile, General Motors stood at the third position, with its EV sales rising 365% to 36,322 units. As part of its goal to accelerate its presence in the EV space, GM entered into an agreement with Tesla last month, which will give its EV buyers access to the Tesla Supercharger network. While GM is cutting costs in several areas, the company continues to invest in its EV ambitions and aims to manufacture 400,000 EVs in North America through the first half of 2024 On Friday, Morgan Stanley analyst Adam Jonas raised his price target for General Motors to $41 from $38 and reiterated a Buy rating. Ahead of the Q2 results, the analyst expects stronger-than-anticipated price and mix and a surprisingly resilient auto consumer to “create beat-and-raise conditions” for the U.S. automakers. Is GM Stock a Good Buy Now? Wall Street has a Moderate Buy consensus rating on General Motors stock based on seven Buys and seven Holds. The average price target of $46.85 implies over 18% upside. Shares have risen 18% year-to-date. Conclusion Wall Street is cautiously optimistic about AbbVie, PepsiCo, and General Motors amid the ongoing macro pressures. Analysts see higher upside potential in AbbVie from current levels, with the pullback in the stock offering an attractive buying opportunity for the long term. Several analysts are looking beyond the Humira-related headwinds and believe in the growth potential of the company’s newer drugs and an extensive pipeline. The company also offers an attractive dividend yield.   Disclosure

According to Investor’s Business Daily, sales of electric vehicles (EVs), specifically all-electric or battery electric vehicles (BEVs), will reach approximately 500,000 units in the initial half of 2023. This represents a signifi

While analysts are mixed regarding their expectations for Tesla (NASDAQ: TSLA) stock from here, the primary trend of their price targets for the growth stock SEO has recently been up. Analysts have been impressed with the company's better-than-expected second-quarter deliveries a

In this week's video, I cover need-to-know news items related to Tesla (NASDAQ: TSLA) during the week of July 3. Today's video will focus on Tesla's sales numbers in Europe and China, one new automaker adapting the Tesla NACS connector, a price war truce in China, and price cuts

Catalysts can be big drivers for stocks. A positive earnings report, upcoming growth project, or other value driver can catapult a stock. That's why investors should be aware of upcoming catalysts for stocks they own or have on their watchlist.

Rivian (NASDAQ: RIVN) looks likely to hit its 50,000 vehicle production target in 2023 and may blow past it. Travis Hoium covers the latest news in this video.

The artificial intelligence (AI) boom has begun, and Wall Street is very bullish. Bank of America and RBC Capital Markets recently raised their year-end price targets for the S&P 500 (SNPINDEX: ^GSPC), and Goldman Sachs called the index undervalued. All three financial instit

A short trading week still managed to deliver volatility to the equity markets. The primary catalyst was the employment outlook. The ADP report on Thursday showed job growth that was double the analysts’ projection. But the Jobs Report on Friday showed a slight miss. 

The China Association of Auto Manufacturers (CAAM), citing antitrust law, on Saturday retracted a pledge to avoid "abnormal pricing" made two days earlier by 16 automakers, including Tesla..

Disruptive investing has stood out in the stock market for years, driving significant growth in the S&P 500. Whether via Tesla (TSLA) pushing the envelope in electric vehicles or e-commerce names like Shopify (SHOP) challenging physical retailers, disruptive names have outperformed the disrupted. However, the disruptive investing regime may no longer surprise the market, according [...] Read more at ETFtrends.com.

Shares of Rivian Automotive surged more than 18% on Friday as it continued to rally after the electric vehicle (EV) maker reported better-than-expected quarterly deliveries early this week.